Urol. praxi. 2017;18(4):162-164 | DOI: 10.36290/uro.2019.019

Neoadjuvant chemotherapy for muscle-invasive bladder cancer

MUDr. Daniel Macík, MUDr. Michal Staník, Ph.D., doc. MUDr. Jan Doležel, PhD.

Klinika operační onkologie, oddělení urologické onkologie, Masarykův onkologický ústav Brno

Radical cystectomy with pelvic lymph node dissection is a standard of treatment for muscle-invasive bladder cancer. However, nomajor improvement of oncological results was seen in the last 30 years. The multimodal therapy was introduced to achieve bettersurvival of the patients. The muscle-invasive bladder cancer started to be considered a systemic disease as 30–50% of cT2–4N0tumors have occult metastatic disease at the time of radical cystectomy. Based on experience with palliative chemotherapy formetastatatic disease, cisplatin-based perioperative chemotherapy was introduced into treatment algorithm of muscle-invasivetumors. In these patients, randomized trials with neoadjuvant chemotherapy showed a 5 % benefit in overall survival.

Keywords: muscle invasive bladder cancer, radical cystectomy, neoadjuvant chemotherapy

Received: April 24, 2019; Accepted: May 27, 2019; Prepublished online: June 7, 2019; Published: November 1, 2017  Show citation